ANDAINTRAVENOUSSOLUTION
Approved
Mar 2022
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
IOFLUPANE I-123 (ioflupane i-123) by Curium Pharma is radiopharmaceutical activity [moa]. First approved in 2022.
Drug data last refreshed Yesterday
Mechanism of Action
Radiopharmaceutical Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Curium Pharma
France - Paris
Worked on IOFLUPANE I-123 at Curium Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.